Fig. 4: PET-derived prognostic pathways guide drug repurposing.
From: Unbiased discovery of cancer pathways and therapeutics using Pathway Ensemble Tool and Benchmark
a Schematic of drug screening aims; computational screen searches for drugs that upregulate expressions of genes from pathways with favorable prognosis and downregulate expressions of genes from pathways with unfavorable prognosis. b Elbow plots showing the significance of overlap between drug up (or down) regulated genes with leading genes from pathways with favorable (or unfavorable) prognostic potential. Drugs are sorted based on the significance (see Methods). Top two drugs for each cancer type are highlighted. c Sankey plot showing top pathways associated with unfavorable prognosis for each cancer type on the left and top two predicted drugs that demote expression of genes in indicated pathway on the right. The thicknesses of links are proportional to the significance of the pathway (E-value > 5; left; see Methods) or the number of genes affected by drug (right). Only drugs that have a significant impact on the top prognosis pathways for each cancer are displayed. As a result, cancers without drugs affecting their top predicted prognosis pathways are not displayed. Source data are provided as a Source Data file.
